Likewise, the predictive performance of an alternative Immunoscore, using a digital image analysis application to characterize immune infiltrate expression of CD3, CD8, CD20, FOXP3 and CD163 and of PD-L1, was tested in a metastatic melanoma cohort of patients treated with Ipilimumab in the MISIPI trial (22, 72). The gene discussed is CD8A; the disease is metastatic melanoma.